Magenta Therapeutics Inc (MGTA)


Stock Price Forecast

Sept. 11, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Magenta Therapeutics Inc chart...

About the Company

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.

Employees

69

CEO

Jason Gardner

Exchange

NASDAQ

Website

www.magentatx.com

$M

Total Revenue

69

Employees

$78M

Market Capitalization

-1.10

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $MGTA News

Stifel starts Dianthus at buy, cites market potential of lead drug

1mon ago, source: Hosted on MSN

The investment firm set its price target for the stock at $44. Dianthus merged with Magenta Therapeutics last year.

Dianthus Therapeutics (DNTH) Price Target Increased by 22.22% to 35.53

23d ago, source: Hosted on MSN

Dianthus Therapeutics Background Information (This description is provided by the company.) magenta therapeutics is a biotechnology company harnessing the power of stem cell science to ...

Dianthus Therapeutics Inc (DNTH)

24d ago, source: Investing

On Wednesday, Stifel initiated coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and a price target of $44.00. The firm's positive outlook is anchored on ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.

Third Rock Ventures GP IV, L.P.'s Net Worth

1mon ago, source: Benzinga.com

Inc., Relay Therapeutics, Inc., and Magenta Therapeutics, Inc.. Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to ...

Kintara Therapeutics Inc KTRA

18h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Ovid Therapeutics Inc OVID

13h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

EFTR eFFECTOR Therapeutics, Inc.

4d ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments

2d ago, source: Seeking Alpha

VistaGen Therapeutics, Inc. (NASDAQ:VTGN), established in 1998 and headquartered in South San Francisco, California, is ...

Q4 2023 Intellia Therapeutics Inc Earnings Call

25d ago, source: Yahoo Finance

Ian Karp; SVP, IR and Corporate Communications; Intellia Therapeutics Inc John Leonard; President & CEO; Intellia Therapeutics Inc David Lebwohl; Chief Medical Officer; Intellia Therapeutics Inc ...

Dianthus Therapeutics Inc (DNTH)

1mon ago, source: Investing

Benzinga - by Lisa Levin, Benzinga Editor. Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) shares gained 35.8% to $21.69 in pre-market trading. Crinetics said Once-daily ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...